Daily Anesthesiology Research Analysis
Three perioperative anesthesia studies stand out today: a randomized trial shows tight intraoperative glucose control markedly reduces postoperative pneumonia after minimally invasive esophagectomy; a double-blind RCT demonstrates low-dose esketamine stabilizes hemodynamics during induction without delaying recovery; and a meta-analysis of 11 RCTs supports short-term NSAID use after cardiac surgery to reduce pain and opioid consumption without increasing adverse events.
Summary
Three perioperative anesthesia studies stand out today: a randomized trial shows tight intraoperative glucose control markedly reduces postoperative pneumonia after minimally invasive esophagectomy; a double-blind RCT demonstrates low-dose esketamine stabilizes hemodynamics during induction without delaying recovery; and a meta-analysis of 11 RCTs supports short-term NSAID use after cardiac surgery to reduce pain and opioid consumption without increasing adverse events.
Research Themes
- Perioperative hemodynamic stabilization
- Glycemic control to prevent postoperative complications
- Opioid-sparing multimodal analgesia after cardiac surgery
Selected Articles
1. Intraoperative tight blood glucose control reduces the incidence of postoperative pneumonia in minimally invasive esophagectomy: a randomized clinical trial.
In a single-blind randomized trial of minimally invasive esophagectomy, targeting intraoperative glucose 4.4–6.1 mmol/L significantly reduced postoperative pneumonia (11.4% vs 34.1%). Inflammatory response (POD1 CRP) and need for advanced antibiotics were also lower with tight control.
Impact: Demonstrates outcome-level benefits of intraoperative glycemic targeting on a clinically meaningful endpoint, informing anesthesia-led protocols for high-risk thoracic GI surgery.
Clinical Implications: Adopting protocolized tight glucose control during minimally invasive esophagectomy may reduce postoperative pneumonia and inflammation. Implementation requires frequent glucose monitoring, insulin titration algorithms, and hypoglycemia safeguards.
Key Findings
- Postoperative pneumonia incidence was lower with tight intraoperative glucose control (11.4%) versus routine control (34.1%).
- POD1 C-reactive protein was reduced with tight control (median 78.3 vs 95.6).
- Fewer patients required advanced antibiotics with tight control (63.4% vs 83.7%).
Methodological Strengths
- Randomized, single-blind design with predefined primary clinical endpoint
- Trial registration and intention-to-treat analysis reported
Limitations
- Single-center study with modest sample size limits generalizability
- Short follow-up; hypoglycemia events and broader safety profile not fully detailed
Future Directions: Multicenter pragmatic RCTs across thoracic and upper GI surgeries to validate pneumonia reduction, assess hypoglycemia risk-benefit, and evaluate protocol implementation and cost-effectiveness.
BACKGROUND: Postoperative pneumonia is a common and fatal complication in minimally invasive esophagectomy patients and is related to perioperative blood glucose. This study hypothesized that compared to dealing with intraoperative blood glucose routinely, tight blood glucose control can reduce the incidence of postoperative pneumonia in minimally invasive esophagectomy patients. METHODS: In this randomized single- blind trial, 88 patients were randomly assigned (1:1) to the tight blood glucose control (4.4-6.1 mmol/L) or non-tight blood glucose control (blood glucose under 10 mmol/L). The primary outcome was the incidence of postoperative pneumonia. The intraoperative insulin-related complications, postoperative inflammation level, blood glucose level, surgical complications, and other secondary outcomes were also assessed. RESULTS: In total, 88 patients were randomized, and 84 patients were included in the analysis. The intention-to-treat analysis showed the incidence of postoperative pneumonia in the tight blood glucose control group (5 of 44 [11.4%]) was significantly lower than non-tight blood glucose control group (15 of 44 [34.1%]) (OR = 0.569, 95% CI: 0.39 to 0.83, P = 0.011). The C-reactive protein on postoperative day 1 was 78.3 (30.4-103.7) in the tight blood glucose control group and 95.6 (79.0-130.5) in the non-tight blood glucose control group (P = 0.008). Compared to the non-tight blood glucose control group (36 of 43 [83.7%]), the demand for advanced antibiotics was lower in the tight blood glucose control group (26 of 41 [63.4%]) (P = 0.034). CONCLUSION: Intraoperative tight blood glucose control is beneficial in reducing the incidence of postoperative pneumonia for minimally invasive esophagectomy patients. REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300077993.
2. Esketamine attenuates hemodynamic oscillations during anesthesia induction in elderly gastrointestinal surgical patients: a randomized trial.
Adjunctive 0.2 mg/kg IV esketamine during propofol-based induction reduced hemodynamic instability from 55.9% to 29.3%, decreased hypotension and hypertension events, lowered ephedrine use, and preserved cardiac output, without prolonging recovery.
Impact: Provides randomized, double-blind evidence for a simple intra-induction intervention that improves cardiovascular stability—an area with immediate implications for anesthesia safety.
Clinical Implications: Low-dose esketamine can be considered to mitigate induction hypotension and oscillations, particularly in fasting, frail, or vasoplegia-prone patients. Incorporate screening for contraindications and monitor for psychomimetic effects.
Key Findings
- Hemodynamic instability during induction was reduced with esketamine (29.3% vs 55.9%; OR 0.33, 95% CI 0.18–0.60).
- Hypotension (27.2% vs 44.1%) and hypertension (3.3% vs 12.9%) events were both decreased.
- Cardiac output was preserved with esketamine; recovery metrics and PONV were unchanged.
Methodological Strengths
- Prospective double-blind randomized controlled design with trial registration
- Objective hemodynamic endpoints including cardiac output and standardized induction protocol
Limitations
- Single-center; sample size not reported in abstract limits precision assessment
- Short observation window focused on induction; generalizability to other populations requires confirmation
Future Directions: Larger multicenter RCTs across diverse surgical populations to confirm efficacy, define optimal dosing, and evaluate safety in cardiovascular and neuropsychiatric subgroups.
BACKGROUND: Patients undergoing gastrointestinal tumor surgery face heightened susceptibility to hemodynamic instability during anesthesia induction, a risk further exacerbated by preoperative fasting. Oscillatory blood pressure fluctuations increase perioperative risks. Esketamine's sympathomimetic properties may counteract propofol-induced hypotension. This study aimed to evaluate the impact of adjunctive esketamine on hemodynamic instability incidence during induction. METHODS: This prospective, double-blind RCT (ChiCTR2200060641, registered on June 6, 2022) enrolled ASA I-III patients (18-75 years) scheduled for gastrointestinal tumor surgery at Foshan First People's Hospital (Jun 2022-May 2023). Patients were randomized 1:1 to receive IV esketamine (0.2 mg/kg) or saline placebo during induction. Anesthesia was induced with propofol (1.5-2.0 mg/kg), sufentanil (0.2 µg/kg), and cisatracurium (0.3 mg/kg). The primary outcome was the incidence of hemodynamic instability (defined as hypertension [MAP > 20% baseline], hypotension [MAP < 65 mmHg or > 20% decrease], tachycardia [HR > 100 bpm], bradycardia [HR < 50 bpm], or vasopressor use) from induction to 5 min post-intubation. The secondary outcomes included intraoperative ephedrine consumption, postoperative recovery time, extubation time, duration of post-anaesthesia care unit (PACU) stay, emergence agitation, cough during intubation, and other adverse effects. RESULTS: The incidence of hemodynamic instability was significantly lower in the esketamine group than in the control group during induction (29.3% vs. 55.9%; OR = 0.33, 95% CI: 0.18-0.60; P < 0.001). Specifically, esketamine reduced hypotension (27.2% vs. 44.1%; P = 0.016) and hypertension (3.3% vs. 12.9%; P = 0.016). Ephedrine use was lower (12.0% vs. 24.7%; P = 0.025). CO was preserved in the esketamine group but declined significantly in the control group post-induction (P < 0.05). Cough incidence was reduced with esketamine (8.7% vs. 32.3%; P < 0.001). No differences existed in recovery times, emergence agitation, or PONV. CONCLUSIONS: Adjunctive low-dose esketamine (0.2 mg/kg) during propofol-based induction significantly attenuates hemodynamic instability and preserves cardiac output in gastrointestinal surgery patients, without delaying recovery. This approach enhances cardiovascular safety during high-risk induction. TRIAL REGISTRATION: This study was registered with the Chinese Clinical Trial Registry (ChiCTR2200060641) on June 6, 2022.
3. Nonsteroidal Anti-Inflammatory Drugs as Part of a Multimodal Postoperative Pain Management Strategy in Patients Undergoing Cardiac Surgery: A Meta-Analysis of 11 Randomized Clinical Trials.
Across 11 randomized trials (n=1,463), adding NSAIDs to opioids after cardiac surgery reduced pain scores at 12–48 hours and decreased opioid consumption at 24–48 hours without detected increases in MI, AF, AKI, or GI bleeding.
Impact: Synthesizes RCT evidence to support NSAID use in a traditionally high-risk population, informing opioid-sparing protocols while addressing safety concerns.
Clinical Implications: Short-term NSAID incorporation into multimodal analgesia after cardiac surgery can modestly improve pain control and reduce opioid exposure. Apply patient selection (renal function, bleeding risk, graft considerations), dose limits, and monitoring.
Key Findings
- Lower VAS pain scores with NSAIDs at 12h (MD −1.19), 18h (MD −1.43), 24h (MD −0.61), and 48h (MD −0.68).
- Reduced opioid consumption at 24h (MD −8.10) and 48h (MD −7.13).
- No significant differences detected in GI bleeding, atrial fibrillation, myocardial infarction, or AKI.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with random-effects modeling
- assessment of both efficacy (pain, opioid use) and safety outcomes
Limitations
- Modest total sample size and heterogeneity in NSAID types/dosing limit detection of rare harms
- Short follow-up windows focus on early postoperative period; long-term graft patency not assessed
Future Directions: Large, adequately powered RCTs comparing specific NSAID regimens with standardized renal and bleeding risk stratification, and longer-term outcomes including graft patency and AKI recovery trajectories.
BACKGROUND: Effective and safe pain management is crucial for optimal recovery after cardiac surgery. Traditionally, opioids have been the mainstay for postoperative pain control, but their negative health effects have led to a recent shift toward multimodal analgesia to minimize opioid use. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been controversial owing to concerns about bleeding, acute kidney injury (AKI), graft patency, and cardiovascular risks. Despite these concerns, many perioperative teams continue to use NSAIDs alongside opioids as part of multimodal analgesia. This meta-analysis evaluated the efficacy and safety of NSAIDs as a multimodal pain management tool following cardiac surgery. METHODS: An electronic search was conducted on November 15, 2024, using PubMed, Scopus, Web of Science, Embase, and Cochrane databases. Only controlled trials that combined NSAIDs with opioids for pain management following cardiac surgeries were included. The primary outcome was the visual analog scale (VAS), a 0 to 10 scale measuring pain intensity assessed at 6, 12, 18, 24, and 48 hours. Total opioid consumption was measured at 6, 12, 24, and 48 hours. Secondary outcomes included myocardial infarction, atrial fibrillation, kidney function, gastrointestinal bleeding, nausea, and vomiting. The mean difference (MD) was used for continuous outcomes, and the odds ratio (OR) was used for dichotomous outcomes. A random-effects model was applied for the analysis. RESULTS: Out of the 1,194 articles screened, 11 articles, totaling 1,463 patients, were included in the meta-analysis. The NSAID group demonstrated significantly lower VAS scores at the 12-hour (MD, -1.19, 95% confidence interval [CI], -1.83 to -0.56; p < 0.001), 24-hour (MD, -0.61; 95% CI, -0.97 to -0.24; p = 0.001), 18-hour (MD, -1.43; 95% CI, -2.58 to -0.28; p = 0.01), and 48-hour (MD, -0.68; 95% CI, -0.87 to -0.49; p < 0.001) time points. However, no significant differences in VAS scores were observed at the 6-hour mark. Regarding opioid consumption, the NSAID group demonstrated significantly lower opioid consumption at the 24-hour (MD, -8.10; 95% CI, -10.60 to -5.61; p < 0.001) and 48-hour (MD, -7.13; 95% CI, -12.44 to -1.82; p = 0.009); however, no differences were observed at the 6-hour and 12-hour marks. Finally, there were no significant differences between the NSAID and control groups in the incidence of gastrointestinal bleeding, atrial fibrillation, myocardial infarction, or AKI. CONCLUSIONS: NSAID use was associated with modestly reduced VAS scores at 12, 18, 24, and 48 hours, while opioid consumption was significantly lower at 24 and 48 hours postoperatively. Short-term NSAID use can be effective in reducing pain and opioid requirements. Although no significant difference in complications was observed, the analysis was limited by small sample sizes. More extensive randomized controlled trials are needed to assess the effectiveness and safety of NSAIDs as part of a multimodal analgesic strategy.